相关实验视频

Updated: May 8, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

在英格兰的早期三阴性乳腺癌患者中,新/辅助化疗时间的区域差异

Laaeba Mirza¹, Luke Steventon^2,3, Rebecca Roylance^3,4

¹University College London, School of Pharmacy, Mezzanine Floor, BMA House, Tavistock Square, London, WC1H 9JP, UK. laaebamirza100@gmail.com.

Breast cancer research and treatment

|September 16, 2024

概括

三阴性乳腺癌 (TNBC) 治疗时间因英格兰的不同地区而异. 手术后化疗时间较长与生存率较差有关,这突显了TNBC患者的护理差异.

科学领域:

在瘤学瘤学.
医疗保健服务研究医疗服务研究
健康公平卫生公平

背景情况:

三阴性乳腺癌 (TNBC) 是一种与预后不佳相关的侵袭性亚型.
治疗包括手术和化疗,延迟影响生存.
了解治疗时间的区域和种族差异对于公平的护理至关重要.

研究的目的:

调查英国TNBC患者的化疗时间 (TTC) 和手术时间 (TTS) 的区域和种族差异.
为了评估英语TNBC人口中的护理公平性.

主要方法:

在英格兰对1347名TNBC患者进行了回顾性队列研究.
在不同的英语地区和种族群体中比较TTC和TTS时期.
统计分析以确定治疗途径时间的显著差异.

主要成果:

在TTC中发现了显著的区域差异,中部地区出现了最长的延迟 (中位数为50天).
对于TTS.没有发现任何显著的区域差异.
种族与化疗启动的及时性没有显著关联.

结论:

在英格兰,TNBC患者的TTC存在区域差异.
这些TTC变异可能会影响生存结果,需要进一步调查.
这些发现可以指导化学疗法和癌症护理中心的改进.

关键词:

乳房乳房乳房癌症癌症癌症癌症化疗化疗是一种化学疗法.延迟延迟延迟的时间外科手术医疗外科手术三重负的三重负.

更多相关视频

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...